GlassScriptPhysician profile
Frank G Shechtman
NPI 1730128877
$2,333.83
in general payments reported to CMS, 2019-2025
17 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $129 · 2021: $131 · 2022: $483 · 2023: $563 · 2024: $539 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $623.06 | 2019-2025 | |
| Glaxosmithkline, LLC. | $558.05 | 2022-2025 | Nucala |
| Novartis Pharmaceuticals Corporation | $342.80 | 2022-2025 | |
| Inspire Medical Systems, INC. | $274.54 | 2023-2025 | Inspire |
| Stryker Corporation | $156.07 | 2019-2025 | Scopis Ent, Nasopore, Xpress Loprofile |
| Genzyme Corporation | $77.76 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $71.22 | 2020-2024 | Dupixent |
| Aerin Medical INC. | $45.02 | 2024 | |
| Smith+Nephew, INC. | $42.08 | 2023-2025 | Coblation, Rapid Rhino, Tula |
| Blueprint Medicines Corporation | $24.98 | 2023 | Ayvakit |
| Neurent Medical Limited | $20.08 | 2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Amgen INC. | $19.95 | 2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $19.90 | 2022 | |
| Grifols USA, LLC | $16.05 | 2024 | Xembify |
| Pfizer INC. | $15.07 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.20 | 2020 | |
| Merck Sharp & Dohme LLC | $13.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Shechtman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.